Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

Naunyn-Schmiedeberg's archives of pharmacology - 1 Sept 2026

Jain Anisha, Rosell Rafael, Dharmashekara Chandan, Shreevatsa Bhargav, González-Cao María, Shivakumar Amogha, Kollur Shiva Prasad, Prasad Ashwini, Shivamallu Chandan, Prasad M N Nagendra

Abstract excerpt

KRAS G12C-mutant non-small cell lung cancer (NSCLC) has transitioned from a therapeutically problematic disease to a precision-targetable cancer, anchored by the landmark approvals of sotorasib and adagrasib. Yet despite these advances, responses remain limited in duration and multiple mechanisms of rapid adaptive resistance emerge under inhibitor pressure. These resistance mechanisms define a therapeutic...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Drug Repositioning
Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Proto-Oncogene Proteins p21(ras)

Antineoplastic Agents

Mutation

Animals

Source

Open in PubMed Open full text

Identifiers

PMID: 42283833
DOI: 10.1007/s00210-026-05533-0
PMCID: PMC13593669

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.PMID 42283833Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

Advances in the treatment of KRASG12C mutant non-small cell lung cancer.Semantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Semantic proximity Read ↗

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read ↗

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read ↗

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.